Our Publications

Many of the brilliant researchers involved in the Dendritic Cell Research group have published peer-reviewed papers on their work.

Learn More About Our Publications

Since 2001, our researchers have published over 200 papers on their work.

To access full text versions of these publications, please visit Google Scholar.

  1. Sutherland SIM, Ju X, Horvath LG, Clark GJ. Moving on From Sipuleucel-T: New Dendritic Cell Vaccine Strategies for Prostate Cancer. Front Immunol. 2021;12:641307.
  1. Vuckovic S, Bryant CE, Lau KHA, Yang S, Favaloro J, McGuire HM, et al. Inverse relationship between oligoclonal expanded CD69- TTE and CD69+ TTE cells in bone marrow of multiple myeloma patients. Blood Adv. 2020;4(19):4593-604.
  2. Li Z, Abadir E, Lee K, Clarke C, Bryant CE, Cooper W, et al. Targeting CD83 in mantle cell lymphoma with anti-human CD83 antibody. Clin Transl Immunology. 2020;9(7):e1156.
  3. Hey-Cunningham AJ, Wong C, Hsu J, Fromm PD, Clark GJ, Kupresanin F, et al. Comprehensive analysis utilizing flow cytometry and immunohistochemistry reveals inflammatory changes in local endometrial and systemic dendritic cell populations in endometriosis. Hum Reprod. 2020.
  4. Fromm PD, Silveira PA, Hsu JL, Papadimitrious MS, Lo TH, Ju X, et al. Distinguishing human peripheral blood CD16(+) myeloid cells based on phenotypic characteristics. J Leukoc Biol. 2020;107(2):323-39.
  5. Dix C, Lo TH, Clark G, Abadir E. Measurable Residual Disease in Acute Myeloid Leukemia Using Flow Cytometry: A Review of Where We Are and Where We Are Going. J Clin Med. 2020;9(6).
  6. Abadir E, Silveira PA, Gasiorowski RE, Ramesh M, Romano A, Mekkawy AH, et al. Targeting CD300f to enhance hematopoietic stem cell transplantation in acute myeloid leukemia. Blood Adv. 2020;4(7):1206-16.
  7. Abadir E, Gasiorowski RE, Silveira PA, Larsen S, Clark GJ. Is Hematopoietic Stem Cell Transplantation Required to Unleash the Full Potential of Immunotherapy in Acute Myeloid Leukemia? J Clin Med. 2020;9(2).
  1. Abadir, E., Gasiorowski, R. E., Lai, K., Kupresanin, F., Romano, A., Silveira, P. A., Lo, T. H., Fromm, P. D., Kennerson, M. L., Iland, H. J., Ho, P. J., Hogarth, P. M., Bradstock, K., Hart, D. N. J., and Clark, G. J. (2019). CD300f epitopes are specific targets for acute myeloid leukemia with monocytic differentiation. Mol Oncol. 13: 2107-2120.
  2. Li, Z., Ju, X., Silveira, P. A., Abadir, E., Hsu, W. H., Hart, D. N. J., and Clark, G. J. (2019). CD83: Activation Marker for Antigen Presenting Cells and Its Therapeutic Potential. Front Immunol. 10: 1312.
  3. Lo, T. H., Abadir, E., Gasiorowski, R. E., Kabani, K., Ramesh, M., Orellana, D., Fromm, P. D., Kupresanin, F., Newman, E., Cunningham, I., Hart, D. N. J., Silveira, P. A., and Clark, G. J. (2019). Examination of CD302 as a potential therapeutic target for acute myeloid leukemia. Plos One. 14.
  4. Kong, B. Y., Bolton, H., Kim, J. W., Silveira, P. A., Fromm, P. D., and Clark, G. J. (2019). On the Other Side: Manipulating the Immune Checkpoint Landscape of Dendritic Cells to Enhance Cancer Immunotherapy. Front Oncol. 9: 50.
  5. Abadir, E., Bryant, C., Larsen, S., and Clark, G. J. (2019). Targeting the niche: depleting haemopoietic stem cells with targeted therapy. Bone Marrow Transplant.
  6. Marsh-Wakefield, F., Kruzins, A., McGuire, H. M., Yang, S. H., Bryant, C., de St Groth, B. F., Nassif, N., Byrne, S. N., Gibson, J., Brown, C., Larsen, S., McCulloch, D., Boyle, R., Clark, G., Joshua, D., Ho, P. J., and Vuckovic, S. (2019). Mass Cytometry Discovers Two Discrete Subsets of CD39(-)Treg Which Discriminate MGUS From Multiple Myeloma. Frontiers in Immunology. 10.
  1. Li, Z., Ju, X., Lee, K., Clarke, C., Hsu, J. L., Abadir, E., Bryant, C. E., Pears, S., Sunderland, N., Heffernan, S., Hennessy, A., Lo, T. H., Pietersz, G. A., Kupresanin, F., Fromm, P. D., Silveira, P. A., Tsonis, C., Cooper, W. A., Cunningham, I., Brown, C., Clark, G. J., and Hart, D. N. J. (2018). CD83 is a new potential biomarker and therapeutic target for Hodgkin lymphoma. Haematologica. 103: 655-665.
  2. Hsu, J. L., Bryant, C. E., Papadimitrious, M. S., Kong, B., Gasiorowski, R. E., Orellana, D., McGuire, H. M., Groth, B. F. S., Joshua, D. E., Ho, P. J., Larsen, S., Iland, H. J., Gibson, J., Clark, G. J., Fromm, P. D., and Hart, D. N. (2018). A blood dendritic cell vaccine for acute myeloid leukemia expands anti-tumor T cell responses at remission. Oncoimmunology. 7: e1419114.
  3. Clark, G. J., Silveira, P. A., Hogarth, P. M., and Hart, D. N. J. (2018). The cell surface phenotype of human dendritic cells. Semin Cell Dev Biol. 86: 3-14.
  4. Bryant, C. E., Sutherland, S., Kong, B., Papadimitrious, M. S., Fromm, P. D., and Hart, D. N. J. (2018). Dendritic cells as cancer therapeutics. Semin Cell Dev Biol. 86: 77-88
  1. Shahin, K., Mattar, Z., Silveira, P., Hsu, W. H., Bendall, L., Hart, D., and Bradstock, K. F. (2017). Bone Marrow Graft-Versus-Host Disease in Major Histocompatibility Complex-Matched Murine Reduced-Intensity Allogeneic Hemopoietic Cell Transplantation. Transplantation. 101: 2695-2704.
  1. Suen H, B. C., Hart D, Joshua D. Novel T Cell Therapies for Myeloma. 2016. Annals of Hematology and Oncology. 3.
  2. Suen, H., Brown, R., Yang, S., Weatherburn, C., Ho, P. J., Woodland, N., Nassif, N., Barbaro, P., Bryant, C., Hart, D., Gibson, J., and Joshua, D. Multiple myeloma causes clonal T-cell immunosenescence: identification of potential novel targets for promoting tumour immunity and implications for checkpoint blockade. 2016. Leukemia. 30: 1716-24.
  3. Seldon, T. A., Pryor, R., Palkova, A., Jones, M. L., Verma, N. D., Findova, M., Braet, K., Sheng, Y., Fan, Y., Zhou, E. Y., Marks, J. D., Munro, T., Mahler, S. M., Barnard, R. T., Fromm, P. D., Silveira, P. A., Elgundi, Z., Ju, X., Clark, G. J., Bradstock, K. F., Munster, D. J., and Hart, D. N. Immunosuppressive human anti-CD83 monoclonal antibody depletion of activated dendritic cells in transplantation. 2016. Leukemia. 30: 692-700.
  4. Lo, T. H., Silveira, P. A., Fromm, P. D., Verma, N. D., Vu, P. A., Kupresanin, F., Adam, R., Kato, M., Cogger, V. C., Clark, G. J., and Hart, D. N. Characterization of the Expression and Function of the C-Type Lectin Receptor CD302 in Mice and Humans Reveals a Role in Dendritic Cell Migration. 2016. J Immunol. 197: 885-98.
  5. Ju, X., Silveira, P. A., Hsu, W. H., Elgundi, Z., Alingcastre, R., Verma, N. D., Fromm, P. D., Hsu, J. L., Bryant, C., Li, Z., Kupresanin, F., Lo, T. H., Clarke, C., Lee, K., McGuire, H., Fazekas de St Groth, B., Larsen, S. R., Gibson, J., Bradstock, K. F., Clark, G. J., and Hart, D. N. The Analysis of CD83 Expression on Human Immune Cells Identifies a Unique CD83+-Activated T Cell Population. 2016. J Immunol. 197: 4613-25.
  6. Joshua, D., Suen, H., Brown, R., Bryant, C., Ho, P. J., Hart, D., and Gibson, J. The T Cell in Myeloma. 2016. Clin Lymphoma Myeloma Leuk. 16: 537-42.
  7. Fromm, P. D., Papadimitrious, M. S., Hsu, J. L., Van Kooten Losio, N., Verma, N. D., Lo, T. H., Silveira, P. A., Bryant, C. E., Turtle, C. J., Prue, R. L., Vukovic, P., Munster, D. J., Nagasaki, T., Barnard, R. T., Mahler, S. M., Anguille, S. A., Berneman, Z., Horvath, L. G., Bradstock, K. F., Joshua, D. E., Clark, G. J., and Hart, D. N. CMRF-56(+) blood dendritic cells loaded with mRNA induce effective antigen-specific cytotoxic T-lymphocyte responses. 2016. Oncoimmunology. 5: e1168555.
  8. Fromm, P. D., Kupresanin, F., Brooks, A. E., Dunbar, P. R., Haniffa, M., Hart, D. N., and Clark, G. J. A multi-laboratory comparison of blood dendritic cell populations. 2016. Clin Transl Immunology. 5: e68.
  9. Clark, G. J., Kupresanin, F., Fromm, P. D., Ju, X., Muusers, L., Silveira, P. A., Elgundi, Z., Gasiorowski, R. E., Papadimitrious, M. S., Bryant, C., Lee, K. M., Clarke, C. J., Young, J. W., Chan, A., Harman, A., Botting, R., Cabezon, R., Benitez-Ribas, D., Brooks, A. E., Dunbar, P. R., and Hart, D. N. New insights into the phenotype of human dendritic cell populations. 2016. Clin Transl Immunology. 5: e61.
  10. Clark, G., Stockinger, H., Balderas, R., van Zelm, M. C., Zola, H., Hart, D., and Engel, P. Nomenclature of CD molecules from the Tenth Human Leucocyte Differentiation Antigen Workshop. 2016. Clin Transl Immunology. 5: e57.
  11. Bryant, C., Fromm, P. D., Kupresanin, F., Clark, G., Lee, K., Clarke, C., Silveira, P. A., Suen, H., Brown, R., Newman, E., Cunningham, I., Ho, P. J., Gibson, J., Bradstock, K., Joshua, D., and Hart, D. A CD2 high-expressing stress-resistant human plasmacytoid dendritic-cell subset. 2016. Immunol Cell Biol. 94: 447-57.
  1. Prue RL, Vari F, Radford KJ, Tong H, Hardy MY, D’Rozario R, et al. A Phase I Clinical Trial of CD1c (BDCA-1)+ Dendritic Cells Pulsed With HLA-A*0201 Peptides for Immunotherapy of Metastatic Hormone Refractory Prostate Cancer. Journal of immunotherapy. 2015;38(2):71-6.
  2. McAuliffe S, Brown R, Catalano A, Ho PJ, Nassif N, Woodland N, Hart D, Weatherburn C, Yang S, Suen H, Paul C, Joshua D, Gibson J: Using digital polymerase chain reaction to detect minimal residual disease in myeloma by identifying FGFR3 up-regulation. Leukemia & Lymphoma 2015:1-3.
  3. Anguille S, Smits EL, Bryant C, Van Acker HH, Goossens H, Lion E, Fromm PD, Hart DN, Van Tendeloo VF, Berneman ZN: Dendritic Cells as Pharmacological Tools for Cancer Immunotherapy. Pharmacol Rev 2015, 67:731-53.
  4. Engel P, Boumsell L, Balderas R, Bensussan A, Gattei V, Horejsi V, Jin BQ, Malavasi F, Mortari F, Schwartz-Albiez R, Stockinger H, van Zelm MC, Zola H, Clark G: CD Nomenclature 2015: Human Leukocyte Differentiation Antigen Workshops as a Driving Force in Immunology. J Immunol 2015, 195:4555-63.
  1. Verma ND, Hall BM, Plain KM, Robinson CM, Boyd R, Tran GT, et al. Interleukin-12 (IL-12p70) Promotes Induction of Highly Potent Th1-Like CD4(+)CD25(+) T Regulatory Cells That Inhibit Allograft Rejection in Unmodified Recipients. Frontiers in immunology. 2014;5:190.
  2. Hocking J, Schwarer AP, Gasiorowski R, Patil S, Avery S, Gibson J, et al. Excellent outcomes for adolescents and adults with acute lymphoblastic leukemia and lymphoma without allogeneic stem cell transplant: the FRALLE-93 pediatric protocol. Leuk Lymphoma. 2014.
  3. Gasiorowski RE, Clark GJ, Bradstock K, Hart DN. Antibody therapy for acute myeloid leukaemia. British journal of haematology. 2014;164:481-95.
  4. Favaloro J, Liyadipitiya T, Brown R, Yang S, Suen H, Woodland N, et al. Myeloid derived suppressor cells are numerically, functionally and phenotypically different in patients with multiple myeloma. Leuk Lymphoma. 2014:1-8.
  5. Favaloro J, Brown R, Aklilu E, Yang S, Suen H, Hart D, et al. Myeloma skews regulatory T and pro-inflammatory T helper 17 cell balance in favor of a suppressive state. Leuk Lymphoma. 2014;55(5):1090-8.
  6. Brown R, Yang S, Weatherburn C, Gibson J, Ho PJ, Suen H, et al. Phospho-flow detection of constitutive and cytokine-induced pSTAT3/5, pAKT and pERK expression highlights novel prognostic biomarkers for patients with multiple myeloma. Leukemia. 2014.
  7. Ziegler AI, Le Page MA, Maxwell MJ, Stolp J, Guo H, Jayasimhan A, et al. The CD19 signalling molecule is elevated in NOD mice and controls type 1 diabetes development. Diabetologia. 2013;56(12):2659-68.
  1. Wiede F, Fromm PD, Comerford I, Kara E, Bannan J, Schuh W, et al. CCR6 is transiently upregulated on B cells after activation and modulates the germinal center reaction in the mouse. Immunology and cell biology. 2013;91:335-9.
  2. Stolp J, Marino E, Batten M, Sierro F, Cox SL, Grey ST, et al. Intrinsic Molecular Factors Cause Aberrant Expansion of the Splenic Marginal Zone B cell Population in NOD mice Journal of Immunology. 2013;191:97-109.
  3. Simpson AM, Swan MA, Liu GJ, Tao C, O’Brien BA, Ch’ng E, et al. Insulin trafficking in a glucose responsive engineered human liver cell line is regulated by the interaction of ATP-sensitive potassium channels and voltage-gated calcium channels. . In: Dr. Francisco Martin I—-, InTech, DOI: 10.5772/52839 editor. Gene Therapy: Tools and Potential Applications2013. p. 703-46.
  4. Shahin K, Sartor M, Hart DN, Bradstock KF. Alterations in chemokine receptor CCR5 expression on blood dendritic cells correlate with acute graft-versus-host disease. Transplantation. 2013;96(8):753-62.
  5. Plain KM, Verma ND, Tran GT, Nomura M, Boyd R, Robinson CM, et al. Cytokines affecting CD4 T regulatory cells in transplant tolerance. Interleukin-4 does not maintain alloantigen specific CD4CD25 Treg. Transplant immunology. 2013;29:51-9.
  6. Hardy MY, Vari F, Rossetti T, Hart DN, Prue RL. A flow cytometry based assay for the enumeration of regulatory T cells in whole blood. Journal of immunological methods. 2013;390:121-6.
  7. Hall BM, Tran GT, Verma ND, Plain KM, Robinson CM, Nomura M, et al. Do Natural T Regulatory Cells become Activated to Antigen Specific T Regulatory Cells in Transplantation and in Autoimmunity? Frontiers in immunology. 2013;4:208.
  8. Gasiorowski RE, Ju X, Hart DN, Clark GJ. CD300 molecule regulation of human dendritic cell functions. Immunology letters. 2013;149(1-2):93-100.
  9. Gasiorowski R, Gibson J, Watson G, Trotman J, Larsen S. Rapidly fatal post-allogeneic stem cell transplant lymphoproliferative disorder presenting with skin and bone marrow involvement. Pathology. 2013;45(1):81-3.
  10. Cheng HL, Bryant CE, Rooney KB, Steinbeck KS, Griffin HJ, Petocz P, et al. Iron, hepcidin and inflammatory status of young healthy overweight and obese women in australia. PLoS One. 2013;8(7):e68675.
  11. Bryant C, Suen H, Brown R, Yang S, Favaloro J, Aklilu E, et al. Long-term survival in multiple myeloma is associated with a distinct immunological profile which includes proliferative cytotoxic T-cell clones and a favourable Treg/Th17 balance. Blood Cancer Journal 2013;3:e148.
  12. Anguille S, Bryant C. Monoclonal gammopathy of undetermined significance. CMAJ : Canadian Medical Association journal = journal de l’Association medicale canadienne. 2013.
  1. Wilkinson R, Woods K, D’Rozario R, Prue R, Vari F, Hardy MY, et al. Human kallikrein 4 signal peptide induces cytotoxic T cell responses in healthy donors and prostate cancer patients. Cancer Immunol Immunother. 2012;61(2):169-79.
  2. Tran GT, Hodgkinson SJ, Carter NM, Verma ND, Plain KM, Boyd R, et al. IL-5 promotes induction of antigen-specific CD4+CD25+ T regulatory cells that suppress autoimmunity. Blood. 2012;119(19):4441-50.
  3. Stolp J, Chen YG, Cox SL, Henck V, Zhang W, Tsaih SW, et al. Subcongenic analyses reveal complex interactions between distal chromosome 4 genes controlling diabetogenic B cells and CD4 T cells in nonobese diabetic mice. J Immunol. 2012;189(3):1406-17.
  4. Li S, Roberts S, Plebanski M, Gouillou M, Spelman T, Latour P, et al. Induction of multi-functional T cells in a phase I clinical trial of dendritic cell immunotherapy in hepatitis C virus infected individuals. PLoS One. 2012;7(8):e39368.
  5. Kassianos AJ, Hardy MY, Ju X, Vijayan D, Ding Y, Vulink AJ, et al. Human CD1c (BDCA-1)+ myeloid dendritic cells secrete IL-10 and display an immuno-regulatory phenotype and function in response to Escherichia coli. European journal of immunology. 2012;42(6):1512-22.
  6. Jeet V, Russell PJ, Verma ND, Khatri A. Targeting aurora kinases: a novel approach to curb the growth & chemoresistance of androgen refractory prostate cancer. Current cancer drug targets. 2012;12(2):144-63.
  7. Gray DH, Kupresanin F, Berzins SP, Herold MJ, O’Reilly LA, Bouillet P, et al. The BH3-only proteins Bim and Puma cooperate to impose deletional tolerance of organ-specific antigens. Immunity. 2012;37(3):451-62.
  8. Fromm PD, Kling J, Mack M, Sedgwick JD, Korner H. Loss of TNF signaling facilitates the development of a novel Ly-6C(low) macrophage population permissive for Leishmania major infection. J Immunol. 2012;188(12):6258-66.
  9. Domingos JA, Fromm P, Smith-Keune C, Jerry DR. A robust flow-cytometric protocol for assessing growth rate of hatchery-reared barramundi Lates calcarifer larvae. Journal of fish biology. 2012;80(6):2253-66.
  10. Cheng HL, Bryant C, Cook R, O’Connor H, Rooney K, Steinbeck K. The relationship between obesity and hypoferraemia in adults: a systematic review. Obesity reviews : an official journal of the International Association for the Study of Obesity. 2012;13(2):150-61.
  11. Brown R, Kabani K, Favaloro J, Yang S, Ho PJ, Gibson J, et al. CD86+ or HLA-G+ can be transferred via trogocytosis from myeloma cells to T cells and are associated with poor prognosis. Blood. 2012;120(10):2055-63.
  12. Anguille S, Lion E, Tel J, de Vries IJ, Coudere K, Fromm PD, et al. Interleukin-15-induced CD56(+) myeloid dendritic cells combine potent tumor antigen presentation with direct tumoricidal potential. PLoS One. 2012;7(12):e51851.
  1. Singh PP, Joshi S, Russell PJ, Verma ND, Wang X, Khatri A. Molecular chemotherapy and chemotherapy: a new front against late-stage hormone-refractory prostate cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011;17(12):4006-18.
  2. Pisani MJ, Fromm PD, Mulyana Y, Clarke RJ, Korner H, Heimann K, et al. Mechanism of cytotoxicity and cellular uptake of lipophilic inert dinuclear polypyridylruthenium(II) complexes. ChemMedChem. 2011;6(5):848-58.
  3. McGuire HM, Vogelzang A, Ma CS, Hughes WE, Silveira PA, Tangye SG, et al. A subset of interleukin-21+ chemokine receptor CCR9+ T helper cells target accessory organs of the digestive system in autoimmunity. Immunity. 2011;34(4):602-15.
  4. Masson F, Kupresanin F, Mount A, Strasser A, Belz GT. Bid and Bim collaborate during induction of T cell death in persistent infection. J Immunol. 2011;186(7):4059-66.
  5. Marino E, Silveira PA, Stolp J, Grey ST. B cell-directed therapies in type 1 diabetes. Trends in immunology. 2011;32(6):287-94.
  6. Kling J, Gollan R, Fromm P, Korner H. Redundancy of interleukin-6 in the differentiation of T cell and monocyte subsets during cutaneous leishmaniasis. Experimental parasitology. 2011;129(3):270-6.
  7. Hart D. The delivery of effective therapeutic cancer vaccination. Asian J Androl. 2011;13(2):183-4.
  8. Hall BM, Verma ND, Tran GT, Hodgkinson SJ. Distinct regulatory CD4+T cell subsets; differences between naive and antigen specific T regulatory cells. Current opinion in immunology. 2011;23(5):641-7.
  9. Gibson BE, Webb DK, Howman AJ, De Graaf SS, Harrison CJ, Wheatley K. Results of a randomized trial in children with Acute Myeloid Leukaemia: medical research council AML12 trial. British journal of haematology. 2011;155(3):366-76.
  10. Fromm PD, Gottlieb D, Bradstock KF, Hart DN. Cellular therapy to treat haematological and other malignancies: progress and pitfalls. Pathology. 2011;43(6):605-15.
  11. Freeman LM, Lam A, Petcu E, Smith R, Salajegheh A, Diamond P, et al. Myeloma-induced alloreactive T cells arising in myeloma-infiltrated bones include double-positive CD8+CD4+ T cells: evidence from myeloma-bearing mouse model. J Immunol. 2011;187(8):3987-96.
  12. Ding Y, Ju X, Azlan M, Hart DNJ, Clark GJ. Screening of the HLDA9 panel on peripheral blood dendritic cell populations. Immunology letters. 2011;134(2):161-6.
  13. Dean MM, Flower RL, Eisen DP, Minchinton RM, Hart DN, Vuckovic S. Mannose-binding lectin deficiency influences innate and antigen-presenting functions of blood myeloid dendritic cells. Immunology. 2011;132(2):296-305.
  1. Ziegler-Heitbrock L, Ancuta P, Crowe S, Dalod M, Grau V, Hart DN, et al. Nomenclature of monocytes and dendritic cells in blood. Blood. 2010;116(16):e74-80.
  2. Tran GT, Hodgkinson SJ, Carter NM, Killingsworth M, Nomura M, Verma ND, et al. Membrane attack complex of complement is not essential for immune mediated demyelination in experimental autoimmune neuritis. Journal of neuroimmunology. 2010;229(1-2):98-106.
  3. Roomberg A, Kling J, Fromm P, Korner H. Tumor necrosis factor negative bone marrow-derived dendritic cells exhibit deficient IL-10 expression. Immunology and cell biology. 2010;88(8):842-5.
  4. Mount AM, Masson F, Kupresanin F, Smith CM, May JS, van Rooijen N, et al. Interference with dendritic cell populations limits early antigen presentation in chronic gamma-herpesvirus-68 infection. J Immunol. 2010;185(6):3669-76.
  5. Korner H, McMorran B, Schluter D, Fromm P. The role of TNF in parasitic diseases: still more questions than answers. International journal for parasitology. 2010;40(8):879-88.
  6. Kassianos AJ, Jongbloed SL, Hart DN, Radford KJ. Isolation of human blood DC subtypes. Methods Mol Biol. 595. 2009/11/27 ed2010. p. 45-54.
  7. Ju X, Clark G, Hart DN. Review of human DC subtypes. In: Naik S, editor. Methods Mol Biol. 595. 2009/11/27 ed2010. p. 3-20.
  8. Jongbloed SL, Kassianos AJ, McDonald KJ, Clark GJ, Ju XS, Angel CE, et al. Human CD141(+) (BDCA-3)(+) dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens. Journal of Experimental Medicine. 2010;207(6):1247-60.
  9. Jones ML, Seldon T, Smede M, Linville A, Chin DY, Barnard R, et al. A method for rapid, ligation-independent reformatting of recombinant monoclonal antibodies. Journal of immunological methods. 2010;354(1-2):85-90.
  10. Hansen E, Krautwald M, Maczurek AE, Stuchbury G, Fromm P, Steele M, et al. A versatile high throughput screening system for the simultaneous identification of anti-inflammatory and neuroprotective compounds. Journal of Alzheimer’s disease : JAD. 2010;19(2):451-64.
  11. Gowans EJ, Roberts S, Jones K, Dinatale I, Latour PA, Chua B, et al. A phase I clinical trial of dendritic cell immunotherapy in HCV-infected individuals. J Hepatol. 2010;53(4):599-607.
  12. Gay RD, Clarke AW, Elgundi Z, Domagala T, Simpson RJ, Le NB, et al. Anti-TNFalpha domain antibody construct CEP-37247: Full antibody functionality at half the size. mAbs. 2010;2(6):625-38.
  13. Cox SL, Stolp J, Hallahan NL, Counotte J, Zhang W, Serreze DV, et al. Enhanced responsiveness to T-cell help causes loss of B-lymphocyte tolerance to a beta-cell neo-self-antigen in type 1 diabetes prone NOD mice. European journal of immunology. 2010;40(12):3413-25.
  14. Christensen ME, Turner BE, Sinfield LJ, Kollar K, Cullup H, Waterhouse NJ, et al. Mesenchymal stromal cells transiently alter the inflammatory milieu post-transplant to delay graft-versus-host disease. Haematologica. 2010;95(12):2102-10.
  15. Basten A, Silveira PA. B-cell tolerance: mechanisms and implications. Current opinion in immunology. 2010;22(5):566-74.
  1. Wilson J, Cullup H, Lourie R, Sheng YH, Palkova A, Radford KJ, et al. Antibody to the dendritic cell surface activation antigen CD83 prevents acute graft-versus-host disease. Journal of Experimental Medicine. 2009;206(2):387-98.
  2. Wiede F, Roomberg A, Cretney E, Lechner A, Fromm P, Wren L, et al. Age-dependent, polyclonal hyperactivation of T cells is reduced in TNF-negative gld/gld mice. Journal of leukocyte biology. 2009;85(1):108-16.
  3. Verma ND, Plain KM, Nomura M, Tran GT, Robinson C, Boyd R, et al. CD4+CD25+ T cells alloactivated ex vivo by IL-2 or IL-4 become potent alloantigen-specific inhibitors of rejection with different phenotypes, suggesting separate pathways of activation by Th1 and Th2 responses. Blood. 2009;113(2):479-87.
  4. Hardy MY, Kassianos AJ, Vulink A, Wilkinson R, Jongbloed SL, Hart DNJ, et al. NK cells enhance the induction of CTL responses by IL-15 monocyte-derived dendritic cells. Immunology and cell biology. 2009;87(8):606-14.
  5. Cox SL, Silveira PA. Emerging roles for B lymphocytes in Type 1 diabetes. Expert review of clinical immunology. 2009;5(3):311-24.
  6. Clark GJ, Ju XS, Tate C, Hart DNJ. The CD300 family of molecules are evolutionarily significant regulators of leukocyte functions. Trends in immunology. 2009;30(5):209-17.
  7. Clark GJ, Ju XS, Azlan M, Tate C, Ding YT, Hart DNJ. The CD300 molecules regulate monocyte and dendritic cell functions. Immunobiology. 2009;214(9-10):730-6.
  8. Bryant C, Larsen S. Anaemia in pregnancy. The Australian and New Zealand Journal of Obstetrics and Gynaecology. 2009;11(3):17-8.
  1. Wilson NS, Young LJ, Kupresanin F, Naik SH, Vremec D, Heath WR, et al. Normal proportion and expression of maturation markers in migratory dendritic cells in the absence of germs or Toll-like receptor signaling. Immunology and cell biology. 2008;86(2):200-5.
  2. Vulink A, Radford KJ, Melief C, Hart DNJ. Dendritic cells in cancer immunotherapy. In: Vande Woude GF, Klein G, editors. Advances in Cancer Research. 99: Academic Press; 2008. p. 363-407.
  3. Vuckovic S, Abdul Wahid FS, Rice A, Kato M, Khalil D, Rodwell R, et al. Compartmentalization of allogeneic T-cell responses in the bone marrow and spleen of humanized NOD/SCID mice containing activated human resident myeloid dendritic cells. Exp Hematol. 2008;36(11):1496-506.
  4. Vari F, Munster DJ, Hsu JL, Rossetti TR, Mahler SM, Gray PP, et al. Practical blood dendritic cell vaccination for immunotherapy of multiple myeloma. British journal of haematology. 2008;143(3):374-7.
  5. Turner BE, Kambouris ME, Sinfield L, Lange J, Burns AM, Lourie R, et al. Reduced Intensity Conditioning for Allogeneic Hematopoietic Stem-Cell Transplant Determines the Kinetics of Acute Graft-Versus-Host Disease. Transplantation. 2008;86(7):968-76.
  6. Mount AM, Smith CM, Kupresanin F, Stoermer K, Heath WR, Belz GT. Multiple dendritic cell populations activate CD4+ T cells after viral stimulation. PLoS One. 2008;3(2):e1691.
  7. Liu XQ, Hart DNJ, MacPherson GG, Good MF, Wykes MN. Soluble CD38 significantly prolongs the lifespan of memory B-cell responses. Immunology. 2008;125(1):14-20.
  8. Ju XS, Zenke M, Hart DNJ, Clark GJ. CD300a/c regulate type I interferon and TNF-alpha secretion by human plasmacytoid dendritic cells stimulated with TLR7 and TLR9 ligands. Blood. 2008;112(4):1184-94.
  9. Hall BM, Robinson CM, Plain KM, Verma ND, Carter N, Boyd RA, et al. Studies on naive CD4+CD25+T cells inhibition of naive CD4+CD25- T cells in mixed lymphocyte cultures. Transplant immunology. 2008;18(4):291-301.
  10. Dufour FD, Silveira PA, Baxter AG. Interactions between B-lymphocytes and type 1 NKT cells in autoimmune diabetes. Journal of immunotoxicology. 2008;5(2):249-57.
  1. Zola H, Swart B, Banham A, Barry S, Beare A, Bensussan A, et al. CD molecules 2006–human cell differentiation molecules. Journal of immunological methods. 2007;319(1-2):1-5.
  2. Young JW, Merad M, Hart DNJ. Dendritic Cells in Transplantation and Immune-Based Therapies. Biology of Blood and Marrow Transplantation. 2007;13(Supplement 1):23-32.
  3. Vuckovic S, Withers G, Harris M, Khalil D, Gardiner D, Flesch I, et al. Decreased blood dendritic cell counts in type 1 diabetic children. Clinical Immunology. 2007;123(3):281-8.
  4. Silveira PA, Serreze DV, Grey ST. Invasion of the killer B’s in type 1 diabetes. Frontiers in bioscience : a journal and virtual library. 2007;12:2183-93.
  5. Serreze DV, Silveira P. To be an autoreactive B (cell) or not to be: Are lessons learned about this question in Type 1 Diabetes applicable to Autoimmune Thyroiditis. The Thyroid and Autoimmunity2007. p. 104-9.
  6. Plain KM, Boyd R, Verma ND, Robinson CM, Tran GT, Hodgkinson SJ, et al. Transplant tolerance associated with a Th1 response and not broken by IL-4, IL-5, and TGF-beta blockade or Th1 cytokine administration. Transplantation. 2007;83(6):764-73.
  7. McKinlay A, Radford K, Kato M, Field K, Gardiner D, Khalil D, et al. Blood monocytes, myeloid dendritic cells and the cytokines interleukin (IL)-7 and IL-15 maintain human CD4+ T memory cells with mixed helper/regulatory function. Immunology. 2007;120(3):392-403.
  8. Mackay F, Silveira PA, Brink R. B cells and the BAFF/APRIL axis: fast-forward on autoimmunity and signaling. Current opinion in immunology. 2007;19(3):327-36.
  9. Lau J, Sartor M, Bradstock KF, Vuckovic S, Munster DJ, Hart DNJ. Activated circulating dendritic cells after hematopoietic stem cell transplantation predict acute graft-versus-host disease. Transplantation. 2007;83(7):839-46.
  10. Kupresanin F, Chow J, Mount A, Smith CM, Stevenson PG, Belz GT. Dendritic cells present lytic antigens and maintain function throughout persistent gamma-herpesvirus infection. J Immunol. 2007;179(11):7506-13.
  11. Kato M, Khan S, d’Aniello E, McDonald KJ, Hart DNJ. The novel endocytic and phagocytic C-type lectin receptor DCL-1/CD302 on macrophages is colocalized with F-actin, suggesting a role in cell adhesion and migration. Journal of Immunology. 2007;179(9):6052-63.
  12. Hall BM, Plain KM, Verma ND, Tran GT, Boyd R, Robinson CM, et al. Transfer of allograft specific tolerance requires CD4+CD25+T cells but not interleukin-4 or transforming growth factor-beta and cannot induce tolerance to linked antigens. Transplantation. 2007;83(8):1075-84.
  13. Freeman JL, Vari F, Hart DNJ. CMRF-56 immunoselected blood dendritic cell preparations activated with GIVI-CSF induce potent antimyeloma cytotoxic T-cell responses. Journal of immunotherapy. 2007;30(7):740-8.
  14. Fadilah SAW, Vuckovic S, Khalil D, Hart DNJ. Cord blood CD34(+) cells cultured with FLT3L, stem cell factor, interleukin-6, and IL-3 produce CD11c(+) CD1a(-)/c(-) myeloid dendritic cells. Stem Cells and Development. 2007;16(5):849-55.
  15. Davidson C, Verma ND, Robinson CM, Plain KM, Tran GT, Hodgkinson SJ, et al. IL-13 prolongs allograft survival: association with inhibition of macrophage cytokine activation. Transplant immunology. 2007;17(3):178-86.
  16. Clark GJ, Rao M, Ju XS, Hart DNJ. Novel human CD4(+) T lymphocyte subpopulations defined by CD300a/c molecule expression. Journal of leukocyte biology. 2007;82(5):1126-35.
  17. Clark GJ, Jamriska L, Rao M, Hart DNJ. Monocytes immunoselected via the novel monocyte specific molecule, CD300e, differentiate into active migratory dendritic cells. Journal of immunotherapy. 2007;30(3):303-11.
  18. Chen YG, Silveira PA, Osborne MA, Chapman HD, Serreze DV. Cellular expression requirements for inhibition of type 1 diabetes by a dominantly protective major histocompatibility complex haplotype. Diabetes. 2007;56(2):424-30.
  19. Chen YG, Driver JP, Silveira PA, Serreze DV. Subcongenic analysis of genetic basis for impaired development of invariant NKT cells in NOD mice. Immunogenetics. 2007;59(9):705-12.
  20. Belz GT, Zhang L, Lay MD, Kupresanin F, Davenport MP. Killer T cells regulate antigen presentation for early expansion of memory, but not naive, CD8+ T cell. Proceedings of the National Academy of Sciences of the United States of America. 2007;104(15):6341-6.
  21. Belz GT, Wilson NS, Kupresanin F, Mount AM, Smith CM. Shaping naive and memory CD8+ T cell responses in pathogen infections through antigen presentation. Advances in experimental medicine and biology. 2007;590:31-42.
  22. Belz GT, Bedoui S, Kupresanin F, Carbone FR, Heath WR. Minimal activation of memory CD8+ T cell by tissue-derived dendritic cells favors the stimulation of naive CD8+ T cells. Nature immunology. 2007;8(10):1060-6.
  23. Badiee A, Davies N, McDonald K, Radford K, Michiue H, Hart D, et al. Enhanced delivery of immunoliposomes to human dendritic cells by targeting the multilectin receptor DEC-205. Vaccine. 2007;25(25):4757-66.
  24. Ang DK, Brodnicki TC, Jordan MA, Wilson WE, Silveira P, Gliddon BL, et al. Two genetic loci independently confer susceptibility to autoimmune gastritis. International immunology. 2007;19(9):1135-44.
  1. Wilkinson R, Kassianos AJ, Swindle P, Hart DNJ, Radford KJ. Numerical and functional assessment of blood dendritic cells in prostate cancer patients. Prostate. 2006;66(2):180-92.
  2. Verma ND, Boyd R, Robinson C, Plain KM, Tran GT, Hall BM. Interleukin-12p70 prolongs allograft survival by induction of interferon gamma and nitric oxide production. Transplantation. 2006;82(10):1324-33.
  3. Silveira PA, Grey ST. B cells in the spotlight: innocent bystanders or major players in the pathogenesis of type 1 diabetes. Trends in endocrinology and metabolism: TEM. 2006;17(4):128-35.
  4. Silveira PA, Chapman HD, Stolp J, Johnson E, Cox SL, Hunter K, et al. Genes within the Idd5 and Idd9/11 diabetes susceptibility loci affect the pathogenic activity of B cells in nonobese diabetic mice. J Immunol. 2006;177(10):7033-41.
  5. Schnorrer P, Behrens GM, Wilson NS, Pooley JL, Smith CM, El-Sukkari D, et al. The dominant role of CD8+ dendritic cells in cross-presentation is not dictated by antigen capture. Proceedings of the National Academy of Sciences of the United States of America. 2006;103(28):10729-34.
  6. Radford KJ, Turtle CJ, Kassianos AJ, Hart DNJ. CD11c(+) blood dendritic cells induce antigen-specific cytotoxic T lymphocytes with similar efficiency compared to monocyte-derived dendritic cells despite higher levels of MHC class I expression. Journal of immunotherapy. 2006;29(6):596-605.
  7. Nomura M, Plain KM, Verma N, Robinson C, Boyd R, Hodgkinson SJ, et al. The cellular basis of cardiac allograft rejection. IX. Ratio of naive CD4+CD25+ T cells/CD4+CD25- T cells determines rejection or tolerance. Transplant immunology. 2006;15(4):311-8.
  8. Ludowyke RI, Elgundi Z, Kranenburg T, Stehn JR, Schmitz-Peiffer C, Hughes WE, et al. Phosphorylation of nonmuscle myosin heavy chain IIA on Ser1917 is mediated by protein kinase C beta II and coincides with the onset of stimulated degranulation of RBL-2H3 mast cells. J Immunol. 2006;177(3):1492-9.
  9. Khan S, Hsu R, Jones A, Ross IL, Hart DNJ, Kato M. Identification of the dominant translation start site in the attB1 sequence of the pET-DEST42 Gateway vector. Protein Expression and Purification. 2006;49(1):102-7.
  10. Kato M, McDonald KJ, Khan S, Ross IL, Vuckovic S, Chen K, et al. Expression of human DEC-205 (CD205) multilectin receptor on leukocytes. International immunology. 2006;18(6):857-69.
  11. Hsu AKW, Kerr BM, Jones KL, Lock RB, Hart DNJ, Rice AM. RNA Loading of Leukemic Antigens into Cord Blood-Derived Dendritic Cells for Immunotherapy. Biology of Blood and Marrow Transplantation. 2006;12(8):855-67.
  12. Hart D, Venter D. Dendritic cells in leukemia and lymphoma. Leukemia & Lymphoma. 2006;47(4):572-3.
  13. Cooper BJ, Key B, Carter A, Angel NZ, Hart DNJ, Kato M. Suppression and overexpression of adenosylhomocysteine hydrolase-like protein 1 (AHCYL1) influences zebrafish embryo development A – Possible role for AHCYL1 in inositol phospholipid signaling. Journal of Biological Chemistry. 2006;281(32):22471-84.
  14. Collin MP, Hart DNJ, Jackson GH, Cook G, Cavet J, Mackinnon S, et al. The fate of human Langerhans cells in hematopoietic stem cell transplantation. Journal of Experimental Medicine. 2006;203(1):27-33.
  1. Zola H, Swart B, Nicholson I, Aasted B, Bensussan A, Boumsell L, et al. CD molecules 2005: human cell differentiation molecules. Blood. 2005;106(9):3123-6.
  2. Vuckovic S, Khalil D, Angel N, Jahnsen F, Hamilton I, Boyce A, et al. The CMRF58 antibody recognizes a subset of CD123(hi) dendritic cells in allergen-challenged mucosa. Journal of leukocyte biology. 2005;77(3):344-51.
  3. Reifsnyder PC, Li R, Silveira PA, Churchill G, Serreze DV, Leiter EH. Conditioning the genome identifies additional diabetes resistance loci in Type I diabetes resistant NOR/Lt mice. Genes and immunity. 2005;6(6):528-38.
  4. Radford KJ, Vari F, Hart DNJ. Vaccine strategies to treat lymphoproliferative disorders. Pathology. 2005;37(6):534-50.
  5. Radford KJ, Turtle CJ, Kassianos AJ, Vuckovic S, Gardiner D, Khalil D, et al. Immunoselection of functional CMRF-56(+) blood dendritic cells from multiple myeloma patients for immunotherapy. Journal of immunotherapy. 2005;28(4):322-31.
  6. Hart DNJ. Dendritic cell biology evolves into clinical application. Lancet. 2005;365(9454):102-4.
  7. Field K, Vuckovic S, Hart DNJ. Measuring Immunity: Basic Science and Clinical Practice. In: Lotze T, Thomson AW, editors. Dendritic Cells. London: Academic Press; 2005. p. 290-8.
  8. Field K, Vuckovic S, Hart DNJ. Dendritic Cells. In: Michael TL, Angus WT, editors. Measuring Immunity. London: Academic Press; 2005. p. 290-8.
  9. Collin MP, Munster D, Clark G, Wang XN, Dickinson AM, Hart DN. In vitro depletion of tissue-derived dendritic cells by CMRF-44 antibody and alemtuzumab: implications for the control of Graft-versus-host disease. Transplantation. 2005;79(6):722-5.
  10. Clark G, Munster D, Yusuf S, Hart DNJ. Eighth Leucocyte Differentiation Antigen Workshop DC Section Summary. Cellular Immunology. 2005;236(1-2):21-8.
  11. Baxter AG, Jordan MA, Silveira PA, Wilson WE, Van Driel IR. Genetic control of susceptibility to autoimmune gastritis. International reviews of immunology. 2005;24(1-2):55-62.
  1. Wykes MN, Beattie L, MacPherson GG, Hart DN. Dendritic cells and follicular dendritic cells express a novel ligand for CD38 which influences their maturation and antibody responses. Immunology. 2004;113(3):318-27.
  2. Vuckovic S, Gardiner D, Field K, Chapman GV, Khalil D, Gill D, et al. Monitoring dendritic cells in clinical practice using a new whole blood single-platform TruCOUNT assay. Journal of immunological methods. 2004;284(1-2):73-87.
  3. Vari F, Hart DNJ. Loading DCs with Ag. Cytotherapy. 2004;6(2):111-21.
  4. Turtle CJ, Hart DNJ. Dendritic cells in tumor immunology and immunotherapy. Current Drug Targets. 2004;5(1):17-39.
  5. Turtle CJ, Brown RD, Joshua DE, Hart DNJ. DC in multiple myeloma immunotherapy. Cytotherapy. 2004;6(2):128-37.
  6. Silveira PA, Dombrowsky J, Johnson E, Chapman HD, Nemazee D, Serreze DV. B cell selection defects underlie the development of diabetogenic APCs in nonobese diabetic mice. J Immunol. 2004;172(8):5086-94.
  7. Senechal B, Boruchov AM, Reagan JL, Hart DNJ, Young JW. Infection of mature monocyte-derived dendritic cells with human cytomegalovirus inhibits stimulation of T-cell proliferation via the release of soluble CD83. Blood. 2004;103(11):4207-15.
  8. Rice AM, Jones KL, Hart DNJ. DC preparations for therapy. Cytotherapy. 2004;6(2):99-104.
  9. Munster DJ, MacDonald KP, Kato M, Hart DJ. Human T lymphoblasts and activated dendritic cells in the allogeneic mixed leukocyte reaction are susceptible to NK cell-mediated anti-CD83-dependent cytotoxicity. International immunology. 2004;16(1):33-42.
  10. Hughes WE, Elgundi Z, Huang P, Frohman MA, Biden TJ. Phospholipase D1 regulates secretagogue-stimulated insulin release in pancreatic beta-cells. The Journal of biological chemistry. 2004;279(26):27534-41.
  11. Hart DNJ, Rice AM, Young JW. Dendritic Cell Immunotherapy. In: Atkinson K, Brenner MK, Champlin R, Fibbe WE, Ljungman P, Ritz J, editors. Clinical bone marrow and blood stem cell transplantation. 3, illustrated, revised ed. Cambridge: Cambridge University Press; 2004. p. 1736-68.
  12. Brown R, Murray A, Pope B, Sze DM, Gibson J, Ho PJ, et al. Either interleukin-12 or interferon-gamma can correct the dendritic cell defect induced by transforming growth factor beta in patients with myeloma. British journal of haematology. 2004;125(6):743-8.
  13. Allan CP, Turtle CJ, Mainwaring PN, Pyke C, Hart DNJ. The immune response to breast cancer, and the case for DC immunotherapy. Cytotherapy. 2004;6(2):154-63.
  1. Vuckovic S, Kim M, Khalil D, Turtle CJ, Crosbie GV, Williams N, et al. Granulocyte-colony stimulating factor increases CD123(hi) blood dendritic cells with altered CD62L and CCR7 expression. Blood. 2003;101(6):2314-7.
  2. Vuckovic S, Hart DNJ. Dendritic cells versus macrophages as antigen presenting cells: common and unique features. In: Gordon S, editor. The macrophage as a therapuetic target. Oxford: Springer; 2003. p. 337-52.
  3. Serreze DV, Silveira PA. The role of B lymphocytes as key antigen-presenting cells in the development of T cell-mediated autoimmune type 1 diabetes. Current directions in autoimmunity. 2003;6:212-27.
  4. MacDonald KPA, Rowe V, Filippich C, Thomas R, Clouston AD, Welply JK, et al. Donor pretreatment with progenipoietin-1 is superior to granulocyte colony-stimulating factor in preventing graft-versus-host disease after allogeneic stem cell transplantation. Blood. 2003;101(5):2033-42.
  5. Lopez JA, Bioley G, Turtle CJ, Pinzon-Charry A, Ho CSK, Vuckovic S, et al. Single step enrichment of blood dendritic cells by positive immunoselection. Journal of immunological methods. 2003;274(1-2):47-61.
  6. Koppi T, Munster DJ, Brown L, MacDonald KPA, Hart DNJ. CMRF-44 antibody-mediated depletion of activated human dendridic cells: A potential means for improving allograft survival. Transplantation. 2003;75(10):1723-30.
  7. Kato M, Khan S, Gonzalez N, O’Neill BP, McDonald KJ, Cooper BJ, et al. Hodgkin’s lymphoma cell lines express a fusion protein encoded by intergenically spliced mRNA for the multilectin receptor DEC-205 (CD205) and a novel C-type lectin receptor DCL-1. Journal of Biological Chemistry. 2003;278(36):34035-41.
  8. Clark GJ, Fitzpatrick S, Kuo CPB, Modra C, Jamriska L, Hart DNJ. The CMRF-35 family of molecules – A new leucocyte receptor complex on chromosome 17. Research Trends in Immunology. 2003;5:55-64.
  9. Barrow L, Brown RD, Murray A, Sze DM, Pope B, Gibson J, et al. CMRF44+ dendritic cells from peripheral blood stem cell harvests of patients with myeloma as potential cellular vectors for idiotype vaccination. Leuk Lymphoma. 2003;44(12):2117-22.
  1. Wykes M, MacDonald KPA, Tran M, Quin RJ, Xing PX, Gendler SJ, et al. MUC1 epithelial mucin (CD227) is expressed by activated dendritic cells. Journal of leukocyte biology. 2002;72(4):692-701.
  2. Vuckovic S, Clark GJ, Hart DNJ. Growth factors, cytokines and dendritic cell development. Current Pharmaceutical Design. 2002;8(5):405-18.
  3. van Driel IR, Baxter AG, Laurie KL, Zwar TD, La Gruta NL, Judd LM, et al. Immunopathogenesis, loss of T cell tolerance and genetics of autoimmune gastritis. Autoimmunity reviews. 2002;1(5):290-7.
  4. Turville SG, Cameron PU, Hart D, Cunningham AL. C-type lectin-HIV attachment on dendritic cells: Innate immune recognition and processing or mediators of HIV transmission? Trends in Glycoscience and Glycotechnology. 2002;14(79):255-71.
  5. Turtle CJ, Hart DNJ. Dendritic cell biiology and application for tumor immunotherapy. Cancer Forum. 2002;26:109-12.
  6. Silveira PA, Johnson E, Chapman HD, Bui T, Tisch RM, Serreze DV. The preferential ability of B lymphocytes to act as diabetogenic APC in NOD mice depends on expression of self-antigen-specific immunoglobulin receptors. European journal of immunology. 2002;32(12):3657-66.
  7. Rice A, Hart D. Technology evaluation: APC-80200, Dendreon. Current Opinion in Molecular Therapeutics. 2002;4(5):523-7.
  8. Osugi Y, Vuckovic S, Hart DNJ. Myeloid blood CD11c(+) dendritic cells and monocyte-derived dendritic cells differ in their ability to stimulate T lymphocytes. Blood. 2002;100(8):2858-66.
  9. Monji T, Petersons JT, Saund NK, Vuckovic S, Hart DNJ, Auditore-Hargreaves K, et al. Competent dendritic cells derived from CD34(+) progenitors express CMRF-44 antigen early in the differentiation pathway. Immunology and cell biology. 2002;80(3):216-25.
  10. McGuckin MA, MacDonald K, Tran M, Wykes M, Hart DNJ. MUCI epithelial mucin – expression by normal haematopoietic cells. In: Mason D, editor. Leucocyte Typing VII. Oxford: Oxford University Press; 2002. p. 496-9.
  11. Mason D, Andre P, Bensussan A, Buckley C, Civin C, Clark E, et al. CD Antigens 2001. Mod Pathol. 2002;15(1):71-6.
  12. Mason D, Andre P, Bensussan A, Buckley C, Civin C, Clark E, et al. Reference: CD Antigens 2002. J Immunol. 2002;168(5):2083-6.
  13. Mason D, Andre P, Bensussan A, Buckley C, Civin C, Clark E, et al. CD antigens 2002. Blood. 2002;99(10):3877-80.
  14. MacDonald KPA, Munster DJ, Clark GJ, Dzionek A, Schmitz J, Hart DNJ. Characterization of human blood dendritic cell subsets. Blood. 2002;100(13):4512-20.
  15. MacDonald K, Munster D, Clark GJ, Vuckovic S, Hart DNJ. Peripheral blood denritic cell subset analysis. In: Mason D, editor. Leucocyte Typing VII. 1. Oxford: Oxford University Press; 2002. p. 315-9.
  16. Lopez JA, Hart DNJ. Current issues in dendritic cell cancer immunotherapy. Current Opinion in Molecular Therapeutics. 2002;4(1):54-63.
  17. Lopez JA, Crosbie G, Kelly C, McGee AM, Williams K, Vuckovic S, et al. Monitoring and isolation of blood dendritic cells from apheresis products in healthy individuals: a platform for cancer immunotherapy. Journal of immunological methods. 2002;267(2):199-212.
  18. Kennedy-Smith AG, McKenzie JL, Owen MC, Davidson PJT, Vuckovic S, Hart DNJ. Prostate specific antigen inhibits immune responses in vitro: A potential role in prostate cancer. Journal of Urology. 2002;168(2):741-7.
  19. Kato M, MacDonald K, Munster D, Vuckovic S, Clark GJ, Hart DNJ. Expression of DEC-205 by human dendritic cells. In: Mason D, editor. Leucocyte Typing VII. 1. Oxford: Oxford University Press; 2002. p. 300-3.
  20. Kato M, MacDonald K, Munster D, Clark GJ, Hart DNJ. CD206 Macrophage mannose receptor panel workshop report. In: Mason D, editor. Leucocyte Typing VII. 1. Oxford: Oxford University Press; 2002. p. 303-6.
  21. Kato M, MacDonald K, Munster D, Clark GJ, Hart DNJ. CD205 (DEC-205) Workshop panel report. In: Mason D, editor. Leucocyte Typing VII. 1. Oxford: Oxford University Press; 2002. p. 298-300.
  22. Jackson DC, Purcell AW, Fitzmaurice CJ, Zeng W, Hart DNJ. The central role played by peptides in the immune response and the design of peptide-based vaccines against infectious diseases and cancer. Current Drug Targets. 2002;3(2):175-96.
  23. Ho CSK, Munster D, Pyke CM, Hart DNJ, Lopez JA. Spontaneous generation and survival of blood dendritic cells in mononuclear cell culture without exogenous cytokines. Blood. 2002;99(8):2897-904.
  24. Hart DNJ, Jackson DJ, Nestle FO. Dendritic cells and cancer: Prospects for cancer vaccination. In: Schuler G, Walden P, editors. Cancer immune therapy: current and furture strategies. 1. Weinheim: Wiley-VCH; 2002. p. 179-201.
  25. Hart DNJ, Clark GJ, Kato M, MacDonald K, Munster D. DC section summary. In: Mason D, editor. Leucocyte Typing VII. 1. Oxford: Oxford University Press; 2002. p. 283-93.
  26. Gemmell E, Carter CL, Hart DNJ, Drysdale KE, Seymour GJ. Antigen-presenting cells in human periodontal disease tissues. Oral Microbiology and Immunology. 2002;17(6):388-93.
  27. Dekker JW, Budhia S, Angel NZ, Cooper BJ, Clark GJ, Hart DNJ, et al. Identification of an S-adenosylhomocysteine hydrolase-like transcript induced during dendritic cell differentiation. Immunogenetics. 2002;53(12):993-1001.
  28. Coventry BJ, Lee PL, Gibbs D, Hart DNJ. Dendritic cell density and activation status in human breast cancer – CD1a, CMRF-44, CMRF-56 and CD-83 expression. British Journal of Cancer. 2002;86(4):546-51.
  29. Clark GJ, Fitzpatrick S, Kuo B, Modra C, Jamriska L, Hart DNJ. Cmrf-35a, Cmrf-35h: Potential New Cd. Journal of Biological Regulators and Homeostatic Agents. 2002;16(3):233-5.
  30. Clark GJ, Colonna M. CD85 Report. Leucocyte Typing VII2002. p. 295-8.
  1. Vuckovic S, Florin THJ, Khalil D, Zhang MF, Patel K, Hamilton I, et al. CD40 and CD86 upregulation with divergent CMRF44 expression on blood dendritic cells in inflammatory bowel diseases. American Journal of Gastroenterology. 2001;96(10):2946-56.
  2. Verma N, He XY, Chen J, Robinson C, Boyd R, Tran G, et al. Interleukin 12 delays allograft rejection: effect mediated via nitric oxide. Transplantation proceedings. 2001;33(1-2):416-7.
  3. Turville SG, Cameron PU, Arthos J, MacDonald K, Clark G, Hart D, et al. Bitter-sweet symphony: defining the role of dendritic cell gp120 receptors in HIV infection. J Clin Virol. 2001;22(3):229-39.
  4. Turville SG, Arthos J, Donald KM, Lynch G, Naif H, Clark G, et al. HIV gp120 receptors on human dendritic cells. Blood. 2001;98(8):2482-8.
  5. Summers KL, Hock BD, McKenzie JL, Hart DNJ. Phenotypic characterization of five dendritic cell subsets in human tonsils. American Journal of Pathology. 2001;159(1):285-95.
  6. Silveira PA, Wilson WE, Esteban LM, Jordan MA, Hawke CG, van Driel IR, et al. Identification of the Gasa3 and Gasa4 autoimmune gastritis susceptibility genes using congenic mice and partitioned, segregative and interaction analyses. Immunogenetics. 2001;53(9):741-50.
  7. Silveira PA, Baxter AG. The NOD mouse as a model of SLE. Autoimmunity. 2001;34(1):53-64.
  8. Serreze DV, Johnson EA, Chapman HD, Graser RT, Marron MP, DiLorenzo TP, et al. Autoreactive diabetogenic T-cells in NOD mice can efficiently expand from a greatly reduced precursor pool. Diabetes. 2001;50(9):1992-2000.
  9. Poulton LD, Smyth MJ, Hawke CG, Silveira P, Shepherd D, Naidenko OV, et al. Cytometric and functional analyses of NK and NKT cell deficiencies in NOD mice. International immunology. 2001;13(7):887-96.
  10. Nestle FO, Banchereau J, Hart D. Dendritic cells: On the move from bench to bedside. Nat Med. 2001;7(7):761-5.
  11. Mason DY, Andre P, Bensussan A, Buckley C, Civin C, Clark E, et al. CD antigens 2001. Tissue Antigens. 2001;58(6):425-30.
  12. Mason D, Andre P, Bensussan A, Buckley C, Civin C, Clark E, et al. CD antigens 2001. Journal of leukocyte biology. 2001;70(5):685-90.
  13. Mason D, Andre P, Bensussan A, Buckley C, Civin C, Clark E, et al. CD antigens 2001: aims and results of HLDA Workshops. Stem Cells. 2001;19(6):556-62.
  14. Johnson EA, Silveira P, Chapman HD, Leiter EH, Serreze DV. Inhibition of autoimmune diabetes in nonobese diabetic mice by transgenic restoration of H2-E MHC class II expression: additive, but unequal, involvement of multiple APC subtypes. J Immunol. 2001;167(4):2404-10.
  15. Hock BD, Kato M, McKenzie JL, Hart DNJ. A soluble form of CD83 is released from activated dendritic cells and B lymphocytes, and is detectable in normal human sera. International immunology. 2001;13(7):959-67.
  16. Ho CSK, Lopez JA, Vuckovic S, Pyke CM, Hockey RL, Hart DNJ. Surgical and physical stress increases circulating blood dendritic cell counts independently of monocyte counts. Blood. 2001;98(1):140-5.
  17. He XY, Verma N, Chen J, Robinson C, Boyd R, Hall BM. IL-5 prolongs allograft survival by downregulating IL-2 and IFN-gamma cytokines. Transplantation proceedings. 2001;33(1-2):703-4.
  18. Hart DNJ, MacDonald K, Vuckovic S, Clark GJ. Phenotypic characterization of dendritic cells. In: Michael TL, Angus WT, editors. Dendritic Cells: Biology and clinical applications. 2 ed. San Diego: Academic Press; 2001. p. 97-117.
  19. Hart DNJ. Broadsheet – Dendritic cells and their emerging clinical applications. Pathology. 2001;33(4):479-92.
  20. Hall BM, Chen J, Robinson C, He XY, Plain K, Verma N, et al. Conditioned dendritic cells as a temporal bridge between T helper and cytotoxic cells. Transplantation proceedings. 2001;33(1-2):195-6.
  21. Clark GJ, Cooper B, Fitzpatrick S, Green B, Hart DNJ. The gene encoding the immunoregulatory signaling molecule CMRF-35A localized to human chromosome 17 in close proximity to other members of the CMRF-35 family. Tissue Antigens. 2001;57(5):415-23.
  22. Brown RD, Pope B, Murray A, Esdale W, Sze DM, Gibson J, et al. Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-beta1 and interleukin-10. Blood. 2001;98(10):2992-8.


We're not around right now. But you can send us an email and we'll get back to you, asap.


©2023 Dendritic Cell Research

Log in with your credentials

Forgot your details?